Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 43063-790

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43063-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063790 Label (43063790)

Medication label for Oxybutynin Chloride Extended Release 10 mg tablets, 90 count. The label includes the NDC 43063-790-90 and is manufactured by PD-Rx Pharmaceuticals, Incorporated in Oklahoma City, OK. It features warnings about drowsiness and alcohol consumption, dosage instructions, reorder number, lot number G19F10, and expiration date 07/2021. The label also displays a barcode and a QR code.*

FDA Label Image

Oxybutynin Chloride Extended Release 1

Chemical structure of oxybutynin chloride, showing its molecular composition including phenyl and cyclohexyl groups, an ester linkage, an alkyne group, and a diethylamino moiety with hydrochloride salt.*

FDA Label Image

Oxybutynin Chloride Extended Release 2

A line graph showing mean plasma R-Oxybutynin concentration (ng/mL) over time (hours) for oxybutynin chloride extended-release tablets 10 mg administered once daily (QD) and oxybutynin 5 mg given three times daily (TID). Concentration curves with error bars illustrate absorption and variability patterns during a 24-hour period.*

FDA Label Image

Oxybutynin Chloride Extended Release 3

Line graph depicting the mean plasma concentration of R-Oxybutynin (ng/mL) over time (hours) up to 24 hours. Data points show concentration fluctuations, peaking around 5 hours and gradually decreasing by 24 hours, with error bars indicating variability.*

FDA Label Image

Oxybutynin Chloride Extended Release 4

A horizontal bar chart comparing mean change in episodes per week from baseline between oxybutynin chloride extended-release tablets and placebo. It shows the mean change with standard deviation bars, with oxybutynin chloride extended-release tablets demonstrating a reduction and placebo close to zero or slight change.*

FDA Label Image

Oxybutynin Chloride Extended Release 5

A horizontal error bar chart depicting mean change (±SD) in episodes per week from baseline for Oxybutynin chloride extended-release tablets and placebo. The chart has a horizontal axis ranging roughly from -40 to 40, showing comparative data for the two groups.*

FDA Label Image

Oxybutynin Chloride Extended Release 6

A horizontal bar chart showing mean change (± SD) in episodes per week from baseline for oxybutynin chloride extended-release tablets and oxybutynin. The x-axis measures mean change from -40 to 40 episodes per week. Both treatments show negative mean changes, indicating a reduction in episodes, with oxybutynin chloride extended-release tablets showing a larger reduction compared to oxybutynin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.